Kymab is a biopharmaceutical company which discovers and develops human monoclonal antibody therapeutics. The Company focuses on using the Kymouse platform for the discovery, development, and commercialization of monoclonal antibodies to difficult and novel drug targets in various therapeutic areas. Its pipeline products cover immuno-oncology, immunology, and opportunistic therapeutic spaces.

Type
Private
HQ
Babraham, GB
Founded
2009
Size (employees)
141 (est)+4%
Website
kymab.com
Kymab was founded in 2009 and is headquartered in Babraham, GB
Report incorrect company information

Key People/Management at Kymab

David Chiswell

David Chiswell

Chief Executive Officer
Bbs Anne Hyland

Bbs Anne Hyland

Chief Financial Officer
Glenn Friedrich

Glenn Friedrich

Chief Operating Officer
Sonia Quaratino

Sonia Quaratino

Chief Medical Officer
Frs Allan Bradley

Frs Allan Bradley

Chief Scientific Officer
Arndt Schottelius

Arndt Schottelius

Executive Vice President, R&D
Show more

Kymab Office Locations

Kymab has offices in Taipei and Babraham
Babraham, GB (HQ)
Meditrina Building, 260 Babraham Research Campus
Show all (2)
Report incorrect company information

Kymab Financials and Metrics

Summary Metrics

Founding Date

2009

Total Funding

$220.4 m

Latest funding size

$100 m

Time since last funding

a year ago

Investors

Kymab's latest funding round in November 2016 was reported to be $100 m. In total, Kymab has raised $220.4 m

Kymab Financials

GBPFY, 2011FY, 2012

Current Assets

1 1

Total Assets

1 1

Additional Paid-in Capital

1 1

Total Equity

1 1
Y, 2012

Financial Leverage

1 x
Show all financial metrics
Report incorrect company information